



Statement of Purdue Pharma regarding July 31 Hearing of the Senate Judiciary Committee

Stamford, CT – July 31, 2007 – In response to today’s hearing, Purdue Pharma stated:

In accepting the settlement agreement recommended by the government that is the subject of today’s hearing, Chief Judge James P. Jones of the United States District Court for the Western District wrote, “In summary, I find that the plea agreements are supported by the facts and the law and impose adequate punishment on the defendants and I accept them.” United States V. The Purdue Frederick Company, Inc., et al., Case No. 1:07CR00029, Opinion and Order, July 23, 2007, at p. 16.

See the Purdue Pharma L.P. web site for prior company statements about this settlement, including measures created under the leadership of the individual defendants to combat abuse and diversion of prescription medications:

http://www.purduepharma.com/pressroom/app/news_announc/wdva_pr.asp

The company also noted that OxyContin[®] (oxycodone HCl controlled-release) Tablets have been and remain available by prescription from licensed healthcare professionals since first found to be safe and effective by the United States Food and Drug Administration (FDA) in 1995. Purdue Pharma will continue to participate in federally-funded health programs and OxyContin will continue to be eligible for coverage by health care programs that use federal dollars, subject to the terms and conditions of the specific health care program in question.

Purdue Pharma L.P. is a research-based pharmaceutical company known for pioneering work on persistent pain. Headquartered in Stamford, CT, Purdue is engaged in the research, development, production, and distribution of both prescription and over-the-counter medicines and hospital products. For years, Purdue has established innovative and effective programs to help physicians, pharmacists and law enforcement combat prescription drug abuse and diversion. Additional information about Purdue can be found at www.purduepharma.com. Program information is available at http://www.purduepharma.com/pressroom/app/news_announc/ss_10ptPlan.asp

--more--

The professional product labeling for OxyContin[®] Tablets contains the following **boxed warning**:

WARNING:

OxyContin is an opioid agonist and a Schedule II controlled substance with an abuse liability similar to morphine.

Oxycodone can be abused in a manner similar to other opioid agonists, legal or illicit. This should be considered when prescribing or dispensing OxyContin in situations where the physician or pharmacist is concerned about an increased risk of misuse, abuse, or diversion.

OxyContin Tablets are a controlled-release oral formulation of oxycodone hydrochloride indicated for the management of moderate to severe pain when a continuous, around-the-clock analgesic is needed for an extended period of time.

OxyContin Tablets are NOT intended for use as a prn analgesic.

OxyContin 60 mg, 80 mg, and 160 mg Tablets, or a single dose greater than 40 mg, ARE FOR USE IN OPIOID-TOLERANT PATIENTS ONLY. A single dose greater than 40 mg, or total daily doses greater than 80 mg, may cause fatal respiratory depression when administered to patients who are not tolerant to the respiratory depressant effects of opioids.

OxyContin TABLETS ARE TO BE SWALLOWED WHOLE AND ARE NOT TO BE BROKEN, CHEWED, OR CRUSHED. TAKING BROKEN, CHEWED, OR CRUSHED OxyContin TABLETS LEADS TO RAPID RELEASE AND ABSORPTION OF A POTENTIALLY FATAL DOSE OF OXYCODONE.

Full prescribing information for OxyContin is available at
<http://www.purduepharma.com/PI/Prescription/Oxycontin.pdf>.

#